Q2 2024 EPS Estimates for Indivior PLC (NASDAQ:INDV) Lowered by Analyst

Indivior PLC (NASDAQ:INDV) – Equities researchers at Northland Capmk decreased their Q2 2024 earnings per share estimates for shares of Indivior in a research note issued to investors on Thursday, April 25th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.46 for the quarter, down from their previous estimate of $0.47. The consensus estimate for Indivior’s current full-year earnings is $2.03 per share. Northland Capmk also issued estimates for Indivior’s Q3 2024 earnings at $0.53 EPS and Q4 2024 earnings at $0.58 EPS.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.15. The business had revenue of $293.00 million for the quarter, compared to analyst estimates of $260.00 million. Indivior had a return on equity of 842.72% and a net margin of 0.44%.

Separately, Craig Hallum assumed coverage on Indivior in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 target price on the stock.

Indivior Trading Down 2.1 %

Shares of INDV opened at $17.56 on Monday. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50. The firm has a market capitalization of $2.42 billion, a P/E ratio of 1,756.00 and a beta of 0.46. The stock’s fifty day simple moving average is $20.51 and its 200 day simple moving average is $18.26. Indivior has a twelve month low of $14.38 and a twelve month high of $26.50.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in INDV. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Indivior by 15.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,596 shares of the company’s stock worth $860,000 after purchasing an additional 5,365 shares in the last quarter. Mackenzie Financial Corp grew its stake in Indivior by 0.3% in the third quarter. Mackenzie Financial Corp now owns 562,595 shares of the company’s stock worth $12,979,000 after purchasing an additional 1,909 shares in the last quarter. Swiss National Bank boosted its stake in Indivior by 1.0% in the third quarter. Swiss National Bank now owns 287,897 shares of the company’s stock valued at $6,257,000 after acquiring an additional 2,727 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in Indivior in the third quarter valued at approximately $801,000. Finally, Liontrust Investment Partners LLP acquired a new position in Indivior in the third quarter valued at approximately $43,340,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.